Various mouse models have been developed and widely exploited in cancer research. To evaluate the efficacy of cancer treatments in preclinical and clinical studies, human tumor xenograft models whereby human cell lines are transplanted into immunocompromized mice are commonly used. In particular, orthotopically implantation of human tumor cells into the equivalent mouse organ where the cancer originated is preferred for demonstrating the effects of new cancer drugs on specific tumors because it provides tumor cells a microenvironment for organotypic interaction which may affect tumor growth, differentiation and its response to drugs. Orthotopic tumor models offer more clinical relevance for tissue site-specific pathology and hence provide prospective evaluation for chemotherapeutic drugs.

With superior skills, Abnova has successfully established several orthotopic human tumor models for researchers to evaluate in vivo efficacy of new compounds for cancer therapy, and more orthotopic models for 8 most common human cancers are in development. With a luciferase expressing cell line directly injected into relevant organ of a live mouse, the orthotopically implanted tumor cells can be easily detected and the growth of tumor in response to anticancer compounds can be monitored in vivo with the IVIS® biophostonic imaging system. Besides providing orthotopic mouse models for different cancers, we also offer customized drug injection service for the convenience of our customers.


  • Increased clinical relevance compared to subcutaneous xenografts
  • Reconstitution of relevant tumor microenvironment
  • Assess of tumor-stromal interactions
  • Site specific study for anti-tumor treatment
  • Use of modeling clinical course of metastatic diseases

Our Services

  • Orthotopic implantation of tumor cells with flawless surgical techniques
  • 8 major tumor types (lung, breast, colon, prostate, liver, pancreas, ovary and spleen)
  • Evaluation of tumor growth in orthotopic xenograft model in vivo
  • Drug treatment with customized methods: s.c., i.p., or i.v.
  • Stable cell lines provided for standard orthotopic efficacy study
  • Our luciferase-labelled tumor cell line available for animal model pre-test/experiment

Developed Orthotopic Mouse Models for Human Cell Lines

Human Cancer Tumor Cell Line Mouse Strain Mouse Organ
Hepatocellular carcinoma HepG2 NOD/SCID/Nude Liver
Lung carcinoma A549 NOD/SCID/Nude Lung
Lung carcinoma CL1-5 NOD/SCID/Nude Lung
Prostate cancer PC3 NOD/SCID/Nude Prostate
*More models are in development and the list is increasing.


Luciferase expression from orthotopic liver tumor in anesthetized NOD/SCID mice
(stable cell line used: HepG2-Luc)
Luciferase expression from orthotopic lung tumor in anesthetized NOD/SCID mice
(stable cell line used: A549-Luc)

Developed Orthotopic Mouse Models for Mouse Cell Lines

Mouse Cancer Tumor Cell Line Mouse Strain Mouse Organ
Colorectal carcinoma CT26 BALB/c Colorectal
Hepatocellular carcinoma BNL 1ME A.7R.1 BALB/c Liver
*More models are in development and the list is increasing.


H&E stain showing colorectal cancer liver metastatic lesions 7 days post-intrasplenic injection in BALB/c mice of CT26 syngeneic murine model.
Tumor volume of the liver cancer BNL 1ME A.7R.1 syngeneic murine model was measured 14 days post tumor cell implantation. The tumor-bearing mice were divided into two groups, non-treated and treated group. Treated group was intravenously injected with anti-tumor drug and non-treated group received PBS. Mice were sacrificed 14 days post-treatment. (A) The results showed that tumor weight was significantly decreased in treated group compared to non-treated group. (B) Images of tumor on liver were showed before treatment (Day0) and 14 days post-treatment.

For any inquiry, please contact :